Compugen (CGEN) Other Accumulated Expenses (2020 - 2021)
Compugen (CGEN) reported Other Accumulated Expenses of $4.8 million for Q4 2021, down 2.91% on a YoY basis from $4.9 million in Q4 2020, and down 2.91% sequentially from $4.9 million in Q4 2020.
Compugen (CGEN) Other Accumulated Expenses (2020 - 2021) Analysis & Trends
Compugen (CGEN) has 2 years of Other Accumulated Expenses data on file, last reported at $4.8 million in Q4 2021.
- For the quarter ending Q4 2021, Other Accumulated Expenses fell 2.91% year-over-year to $4.8 million; the trailing twelve-month figure through Dec 2021 stood at $4.8 million (down 2.91% YoY), and the FY2021 full-year result was $4.8 million, down 2.91% from the prior year.
- Other Accumulated Expenses fell to $4.8 million in Q4 2021, from $4.9 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $4.9 million in Q4 2020 to a low of $4.8 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - |
| 10 | Compugen | 222.68 Mn | 130.93 Mn | 352,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 4.78 Mn |
| Dec 31, 2020 | 4.92 Mn |